Cardiff Oncology Inc CRDF:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/16/24 EDT
3.74quote price arrow up+0.17 (+4.76%)
Volume
362,574
52 week range
0.94 - 6.42
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close3.74
  • 52 Week High6.42
  • 52 Week High Date03/25/24
  • 52 Week Low0.94
  • 52 Week Low Date11/10/23

Key Stats

  • Market Cap167.27M
  • Shares Out44.72M
  • 10 Day Average Volume0.89M
  • Dividend-
  • Dividend Yield-
  • Beta1.89
  • YTD % Change141.22

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close3.74
  • 52 Week High6.42
  • 52 Week High Date03/25/24
  • 52 Week Low0.94
  • 52 Week Low Date11/10/23
  • Market Cap167.27M
  • Shares Out44.72M
  • 10 Day Average Volume0.89M
  • Dividend-
  • Dividend Yield-
  • Beta1.89
  • YTD % Change141.22

RATIOS/PROFITABILITY

  • EPS (TTM)-0.90
  • P/E (TTM)-4.17
  • Fwd P/E (NTM)-3.74
  • EBITDA (TTM)-43.883M
  • ROE (TTM)-51.15%
  • Revenue (TTM)610,000.014
  • Gross Margin (TTM)27.28%
  • Net Margin (TTM)-6,594.92%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cardiff Oncology Inc

 

Profile

MORE
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast...
Rodney Markin M.D., Ph.D.
Independent Chairman of the Board
Mark Erlander Ph.D.
Chief Executive Officer, Director
Vicki Kelemen
Chief Operating Officer
James Levine
Chief Financial Officer
Address
11055 Flintkote Ave
San Diego, CA
92121-1220
United States

Top Peers

SYMBOLLASTCHG%CHG
RANI
Rani Therapeutics Holdings Inc
5.46-0.07-1.27%
RAPT
RAPT Therapeutics Inc
4.14-0.11-2.47%
PRAX
Praxis Precision Medicines Inc
45.21+1.21+2.75%
ACHV
Achieve Life Sciences Inc
5.07-0.14-2.69%
RGLS
Regulus Therapeutics Inc
2.00-0.02-0.99%